We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Antibodies
- Mammalian antibody classes
- Mammalian antibody classes (schematic)
- Mammalian antibody subclasses
- Monoclonal antibodies as therapeutic agents
- IgG is the preferred class
- Crystal structure of whole IgG2a
- Antibody modes of action
- Fc receptors - introduction
- Fc receptors
- Characteristics of human IgG Fc receptors
- Human IgG Fc receptors
- Cell distribution and expression of FcR
- Cell activation by immune complexes
- Cell inhibition by immune complexes
- IgG1-FcRIII complex crystal structure
- The Brambell receptor or FcRn
- The IgG receptor FcRn
- Effect of half-life on antibody concentration
- Pathogen encoded HSV-1 FcR
- Binding of human IgG to cells infected with HSV-1
- Binding of human IgG1 allotype variants to cells
- Human IgG glycosylation effect on binding to cells
- IgG1 allotypes and HSV-1 FcR binding
- IgG1 allotypes
- Effector functions and therapy
- Rodent monoclonal antibodies for therapy
- Effector functions of rodent antibodies (ADCC)
- Effector functions of rat antibodies
- Campath-1 CD52 antigen
- Therapeutic use of Campath-1(CD52) antibodies
- Therapy with rat CD52 antibodies
- Serotherapy with rat IgG2b Campath-1G
- Mechanism of action of Campath-1G Ab
- Problems with use of rodent antibodies for therapy
- Human antibodies for therapeutic applications
- Humanizing the rat IgG2b Campath-1G antibody
- Effector functions of human isotypes
- Rat IgG2b is effective in therapy
- Human IgG1 also effective in therapy
- Effector functions of human IgG
- Summary
- Acknowledgements
Topics Covered
- Antibody classes and subclasses
- General Ab structure
- Modes of action
- Fc receptors
- General FcR structures
- Cellular expression
- Triggering by immune complexes
- Neonatal FcR
- Antibody half-life
- Viral FcR
- Antibody allotypes
- Therapeutic use of monoclonal antibodies
- Mechanisms of action
- Antiglobulin responses
- Antibody humanization
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Clark, M. (2007, October 1). Fc receptors and antibody effector functions [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 6, 2024, from https://doi.org/10.69645/FDUF8583.Export Citation (RIS)
Publication History
Financial Disclosures
- Requested.